CIK 0001815776 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844867570
- Phone
- 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-29 | JIMENEZ JOSEPH Director | Conversion · Series B Preferred Stock | −19,763 | 0 | ||
| 2021-06-29 | KARSEN PERRY A Director | Conversion | +8,126 | 164,034 | ||
| 2021-06-29 | KARSEN PERRY A Director | Conversion · Series B Preferred Stock | −19,763 | 0 | ||
| 2021-06-29 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Conversion | +8,126 | 1,161,670 | ||
| 2021-06-29 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Conversion · Series B Preferred Stock | −19,763 | 0 | ||
| 2021-06-24 | Carlo Rizzuto Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-06-24 | Jerel Davis Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-06-24 | Bassan Abraham Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-04-18 | Gutry Phil CHIEF BUSINESS OFFICER | Option exercise | +3,383 | $6.11 | $21K | 285,345 |
| 2021-04-18 | Gutry Phil CHIEF BUSINESS OFFICER | Option exercise · Stock Option (right to buy) | −3,383 | 159,027 | ||
| 2021-04-15 | Shah Smital Director | Grant or award · Stock Option (right to buy) | +93,585 | 93,585 | ||
| 2021-03-17 | Gutry Phil CHIEF BUSINESS OFFICER | Grant or award · Stock Option (right to buy) | +162,410 | 162,410 | ||
| 2021-03-17 | Gutry Phil CHIEF BUSINESS OFFICER | Grant or award · Stock Option (right to buy) | +69,604 | 69,604 | ||
| 2021-03-17 | Stultz Katherine V CHIEF OPERATING OFFICER | Grant or award · Stock Option (right to buy) | +209,846 | 209,846 | ||
| 2021-03-17 | Stultz Katherine V CHIEF OPERATING OFFICER | Grant or award · Stock Option (right to buy) | +89,934 | 89,934 | ||
| 2021-03-17 | JIMENEZ JOSEPH Director | Grant or award · Stock Option (right to buy) | +12,469 | 12,469 | ||
| 2021-03-17 | KARSEN PERRY A Director | Grant or award · Stock Option (right to buy) | +18,698 | 18,698 | ||
| 2021-03-17 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +795,196 | 795,196 | ||
| 2021-03-17 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +340,798 | 340,798 | ||
| 2021-03-11 | Gutry Phil CHIEF BUSINESS OFFICER | Grant or award · Series B Preferred Stock | +19,763 | $5.06 | $100K | 19,763 |
Page 10 of 11 · 217 trades